Skip to main content

Table 1 Patient demographics and baseline characteristics

From: A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

 

Arm A (N=21)

Arm B (N=7)

Arm C (N=17)

Overall (N=45)

Epertinib + T

Epertinib + T + V

Epertinib + T + C

 

Sex

 Female

21 (100%)

6 (85.7%)

17 (100%)

44 (97.8%)

 Male

0

1 (14.3%)

0

1 (2.2%)

Age (years)

 Mean (range)

57.6 (38-79)

49.0 (36-57)

56.8 (36-75)

56.0 (36-79)

ECOG PS at screening

 0

11 (52.4%)

6 (85.7%)

11 (64.7%)

28 (62.2%)

 1

10 (47.6%)

1 (14.3%)

6 (35.3%)

17 (37.8%)

Number of metastatic sites at screening

 1-3

7 (33.3%)

4 (57.1%)

5 (29.4%)

16 (35.6%)

 ≥4

14 (66.7%)

3 (42.9%)

12 (70.6%)

29 (64.4%)

Number of prior anti-cancer therapy regimens

 1-3

0

1 (14.3%)

6 (35.3%)

7 (15.6%)

 ≥4

21 (100%)

6 (85.7%)

11 (64.7%)

38 (84.4%)

Prior HER2-targeted therapy

 Trastuzumab

21 (100%)

7 (100%)

17 (100%)

45 (100%)

 T-DM1

15 (71.4%)

3 (42.9%)

13 (76.5%)

31 (68.9%)

 Lapatinib

10 (47.6%)

2 (28.6%)

7 (41.2%)

19 (42.2%)

 Pertuzumab

3 (14.3%)

2 (28.6%)

4 (23.5%)

9 (20.0%)

Prior Capecitabine / Vinorelbine

Capecitabine

16 (76.2%)

4 (57.1%)

11 (64.7%)

31 (68.9%)

 Vinorelbine

9 (42.9%)

1 (14.3%)

10 (58.8%)

20 (44.4%)

  1. Abbreviations: T trastuzumab, V vinorelbine, C capecitabine, ECOG Eastern cooperative oncology group, PS performance status